Evidence map›Paper›PMID 41813673›Full record

ArticleNature communications2026

Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors.

Callum Walker, Gabriel Kollarovic, Daniel Weekes, Jennifer Trendell, Ricarda M Hoffmann, Alexia Martin, Riccardo Ferro, Blanca Navarro-Llinas, Luke Hitchen, Mercedes Pardo Calvo and 25 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Callum Walker *The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Gabriel Kollarovic *The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID 0000-0002-3159-7781
Daniel WeekesThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Jennifer TrendellThe Breast Cancer Now Research Unit, King's College London, London, UK.ORCID 0000-0002-5517-0352
Ricarda M HoffmannThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Alexia MartinThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Riccardo FerroThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID 0000-0001-6532-4856
Blanca Navarro-LlinasThe Breast Cancer Now Research Unit, King's College London, London, UK.
Luke HitchenThe Breast Cancer Now Research Unit, King's College London, London, UK.
Mercedes Pardo CalvoThe Institute of Cancer Research, London, UK.ORCID 0000-0002-3477-9695
Nicolae BalanThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Harriet KempThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Alexandra CarrollThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Kathryn DavidsonThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Sarmi NathThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID 0000-0002-8302-7094
Nadja D'UonnoThe Breast Cancer Now Research Unit, King's College London, London, UK.ORCID 0009-0008-5585-7083
Ruifang LuThe Breast Cancer Now Research Unit, King's College London, London, UK.
Chris StarlingThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID 0009-0007-5100-6663
Marieke OttenThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID 0000-0002-1395-2647
Nino IakobachviliThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Chiara MarcozziThe Institute of Cancer Research, London, UK.
Ilhan RahmanThe Breast Cancer Now Research Unit, King's College London, London, UK.
Jelmar QuistThe Breast Cancer Now Research Unit, King's College London, London, UK.
Lu YuThe Institute of Cancer Research, London, UK.ORCID 0000-0001-8378-9112
Dragomir B KrastevThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID 0000-0003-4298-7272
Valeria AmodeoThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Ioannis RoxanisThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Anita GrigoriadisThe Breast Cancer Now Research Unit, King's College London, London, UK.ORCID 0000-0003-3434-201X
Richard BaylissSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.ORCID 0000-0003-0604-2773
Jyoti ChoudharyThe Institute of Cancer Research, London, UK.ORCID 0000-0003-0881-5477
Syed HaiderThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID 0000-0001-6685-5480
Jonathon PinesThe Institute of Cancer Research, London, UK.ORCID 0000-0002-5227-6004
Stephen J PettittThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. Stephen.Pettitt@icr.ac.uk.
Christopher J LordThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. Chris.Lord@icr.ac.uk.ORCID 0000-0002-3226-0515
Andrew N J TuttThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. Andrew.Tutt@icr.ac.uk.ORCID 0000-0001-8715-2901

Funding

Breast Cancer Research Foundation (BCRF) BCRF-23-199Cancer Research UK (CRUK) DRCRPGNov21y100001Wellcome Trust grant
6 · The paper itself

Abstract

HORMAD1 expression is usually restricted to germ-line cells but is also aberrantly expressed in 60% of triple-negative breast cancers (TNBCs), where it is bi-modally expressed and associated with genomic instability. Here, we show that out-of-context HORMAD1 expression in mitotic cells perturbs mitotic arrest and generates aneuploidy. These phenotypes are caused by out-of-context HORMAD1 expression driving a weakening of the spindle assembly checkpoint (SAC) and/or in kinetochore-microtubule error correction. These mitotic effects of HORMAD1 are MAD2L1-independent, but instead caused by a HORMAD1/Aurora B interaction and defective Aurora B/INCENP signalling. Consistent with this mechanism, aberrant HORMAD1 expression causes sensitivity to MPS1, Aurora B or BUB1 inhibitors currently being investigated as cancer treatments. Our data suggests how out-of-context expression of a meiotic gene imparts genomic instability upon tumour cells and also identifies several associated dependencies as mechanism-based therapeutic targets for a large, biomarker-defined, subset of cancers.

Indexed as

Cell Cycle ProteinsMitosisM Phase Cell Cycle CheckpointsProtein Kinase InhibitorsAneuploidyAurora Kinase BCell Line, TumorFemaleGene Expression Regulation, NeoplasticGenomic InstabilityHumansMad2 ProteinsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesSecurinAURKB protein, humanAurora Kinase BBUB1 protein, humanCell Cycle ProteinsMAD2L1 protein, humanMad2 Proteinspituitary tumor-transforming protein 1, humanProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesSecurinTTK protein, human

Identifiers

PMID41813673
PMCPMC12979829

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.